19:39 ET Shareholder Alert: The Ademi Firm investigates whether VYNE Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders
I'm PortAI, I can summarize articles.
The Ademi Firm is investigating VYNE Therapeutics Inc. for potential breaches of fiduciary duty in its transaction with Yarrow Bioscience. VYNE shareholders will own about 3% of the combined company, while Yarrow shareholders will own 97%. The transaction limits competing bids for VYNE, and insiders receive substantial benefits. The investigation focuses on whether VYNE's board is fulfilling its fiduciary duties to shareholders.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: prnewswire The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments